Company Net Income: 4DMT (FDMT)

FDMT (4D Molecular Corp) - company brandmark

4D Molecular Therapeutics creates unique viral vectors, protecting its developments with patents against market pressure from analogs. The firm's strategy relies on the diversification of projects in the fields of lung, heart, and vision treatment. The current profit figure is recorded at -0.18. This price action chart of the asset on the GURU.Markets platform allows for a detailed analysis of the company's stock market movement.

FDMT: 4D Molecular Corp Company Net Income 07/04/2022 - 11/01/2026

Analytical breakdowns for 4D Molecular Therapeutics, Inc. (FDMT)

- price and consensus price forecast:
Stock Quotes 4D Molecular Corp|FDMT - Fair Value Consensus
- company stock exchange capitalization indicators:
Market Value 4D Molecular Corp|FDMT - Real Price to Acquire Entire Company
- book capitalization indicators:
Net Assets per Single Share 4D Molecular Therapeutics|FDMT - Total Stockholders' Equity|Market Value to Book Value Ratio 4dmoleculartherapeutics.com|FDMT - Aggregate Company Assets
- debt and solvency information:
Total Debt to Capital 4D Molecular Therapeutics|FDMT - Long-Term Liabilities to Capital|Short-Term Debt to Capital 4DMT|FDMT - Company Total Debt|Debt to Book Value 4D Molecular Corp|FDMT - Company Long-Term Debts|Company Short-Term Debt 4D Molecular Therapeutics|Quick Ratio 4dmoleculartherapeutics.com
- earnings and valuation multiples information:
FDMT - Net Profit
Summary company analysis:FDMT, 4D Molecular Corp
Manufactured product of 4D Molecular Therapeutics, Inc.

The development of innovative AAV platforms at 4D Molecular Therapeutics (FDMT) is directly reflected in the company's net profitability dynamics. This indicator measures the final financial result after deducting all operating and tax liabilities. Daily calculations calibrate the business valuation, filling information gaps between quarterly reports. Steady growth confirms the effectiveness of clinical trial management. Sharp profit peaks may signal asset overheating, foreshadowing a correction.

Direct competitors

Net Income Tempus AI|QGEN - Final Profit|Company Net Income IONS|Net Income RGEN (Repligen)|Company Net Income RNA (Avidity Biosciences Inc)|CRSP: Company Net Income|GeneDx Corp - Company Net Income|RARE - Company Net Income|BEAM - Net Profit|Company Net Income SRPT|Twist Bioscience Inc (TWST) - Net Profit|Net Income TXG|Net Income Intellia Corp (NTLA)|Net Profit STOK|Company Net Income BLFS (biolifesolutions.com)|Company Net Income Wave Life Sciences Ltd. WVE|Net Profit Maze Therapeutics, Inc. MAZE|Sionna Pharma - Net Profit|PRME: Company Net Income|Final Profit Taysha Gene Therapies TSHA|Net Income uniqure.com|MGTX - Final Profit|Net Income REGENXBIO Inc (RGNX)|Profit After Payment of Taxes Solid Bio|Net Profit Ocugen Pharma (OCGN)|Final Profit Pacific Biosciences|Net Profit benitec.com BNTC|DSGN (Design Therapeutics, Inc.) - Company Net Income|RCKT: Company Net Income|Final Profit lexeotx.com LXEO|Korro Bio (KRRO) - Net Profit|EDIT (Editas Medicine, Inc.) - Net Profit|Company Net Income SLN|PRQR - Profit After Tax|Net Profit codexis.com (CDXS)|SGMO: Company Net Income|NAUT - Net Income|Metagenomi, Inc. - Net Profit|Precision BioSciences Inc. (DTIL) - Net Income|GBIO - Profit After Payment of Taxes|Boundless Bio Inc. (BOLD) - Net Profit|XCUR: Net Financial Result|Net Profit Celsion Corporation|Net Income PHIO (Phio Pharmaceuticals)|Company Net Income MBIO (mustangbio.com)|Net Financial Result RNAZ|Net Profit Bionano Genomics Inc. BNGO|Profit After Tax Applied DNA|BLUE - Net Profit|Company Profit immunoprecise.com|OMGA (omegatherapeutics.com) - Company Net Income|Net Income OMIC|Net Income Regulus Therapeutics, Inc. (RGLS)|Profit After Payment of Taxes Syros|Net Profit Telesis Bio, Inc (TBIO)|TCON - Company Profit|unitybiotechnology.com - Company Net Income